Workflow
上海科华生物工程股份有限公司2025年半年度报告摘要

Core Viewpoint - The company has released its 2025 semi-annual report, confirming that the report accurately reflects its operational results and financial status without any misleading statements or omissions [6][14]. Group 1: Company Overview - The company did not distribute cash dividends or issue new shares during the reporting period [3]. - The number of shareholders and their holdings were disclosed, with a total of 13,696,600 shares held in the company's repurchase account, accounting for 2.66% of the total share capital [4]. Group 2: Board and Supervisory Committee Meetings - The 10th Supervisory Committee meeting was held on August 25, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [6][12]. - The 10th Board of Directors meeting also took place on August 25, 2025, with all nine directors present, including three independent directors, and the meeting adhered to legal requirements [12][14]. Group 3: Fundraising and Usage - The company raised a total of RMB 738 million through the issuance of convertible bonds, with a net amount of RMB 718.53 million after deducting issuance costs [22]. - The company has established special accounts for managing the raised funds, ensuring compliance with regulatory requirements [25]. - As of June 30, 2025, the company reported no changes in the use of raised funds, and all funds remain in designated bank accounts for future investment projects [30][34].